Volume 54, Issue 4, Pages (October 1998)

Slides:



Advertisements
Similar presentations
Volume 69, Issue 11, Pages (June 2006)
Advertisements

Volume 55, Issue 2, Pages (February 1999)
Volume 69, Issue 11, Pages (June 2006)
Plasma sodium and hypertension
Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors  George L. Bakris, M.D, Nancy A. Lass, Dana Glock 
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh  Kidney International 
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  Paul E. De Jong, Barry M. Brenner  Kidney International 
Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh  Kidney International 
Volume 61, Issue 4, Pages (April 2002)
Volume 67, Issue 6, Pages (June 2005)
Volume 59, Issue 1, Pages (January 2001)
Membranous nephropathy: When and how to treat
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes  Robert W. Schrier, Raymond.
Peter Rossing, Philip Hougaard, Hans-Henrik Parving 
Dieter A. Häberle, Wolfgang Biller, Takuyuki Ise, Christian J. Metz 
Volume 65, Issue 6, Pages (June 2004)
Volume 63, Issue 3, Pages (March 2003)
Volume 55, Issue 2, Pages (February 1999)
Volume 57, Pages S32-S37 (April 2000)
Progression of diabetic nephropathy
Volume 74, Issue 3, Pages (August 2008)
Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion  Lynda A. Frassetto, Eileen Nash,
Insulin resistance in African Americans
Renal risk scores: Progress and prospects
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
The role of protein kinase C activation in diabetic nephropathy
Volume 70, Issue 7, Pages (October 2006)
Volume 53, Issue 4, Pages (April 1998)
Volume 82, Issue 7, Pages (October 2012)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Proteinuria and hypertensive nephrosclerosis in African Americans
Volume 74, Issue 8, Pages (October 2008)
Volume 87, Issue 1, Pages (January 2015)
Volume 67, Issue 4, Pages (April 2005)
Counteracting progression of renal disease: A look into the future
Volume 78, Issue 5, Pages (September 2010)
Volume 62, Issue 4, Pages (October 2002)
Volume 60, Issue 1, Pages (July 2001)
Volume 80, Issue 3, Pages (August 2011)
Circadian regulation of renal function
Nina Vasavada, Chandan Saha, Rajiv Agarwal  Kidney International 
Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction  Adam G. McLean, Andrew Davenport, Dominic.
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
The course of the remnant kidney model in mice
Phosphate binders on iron basis: A new perspective?
Volume 53, Issue 6, Pages (June 1998)
Volume 80, Issue 10, Pages (November 2011)
Volume 74, Issue 9, Pages (November 2008)
Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension  Julian Segura, Carlos Campo, Luis M. Ruilope  Kidney.
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 72, Issue 11, Pages (December 2007)
Is it the low-protein diet or simply the salt restriction?
Clinical and cellular markers of diabetic nephropathy
Volume 69, Issue 11, Pages (June 2006)
Renal blood flow in experimental septic acute renal failure
Volume 63, Pages S13-S16 (February 2003)
Volume 56, Issue 4, Pages (October 1999)
Volume 62, Issue 5, (November 2002)
Volume 58, Issue 2, Pages (August 2000)
Membranous nephropathy: recent travels and new roads ahead
Volume 53, Issue 5, Pages (May 1998)
Friends, social networks, and progressive chronic kidney disease
Volume 69, Issue 11, Pages (June 2006)
Volume 57, Issue 2, Pages (October 2000)
Volume 73, Issue 11, Pages (June 2008)
Volume 71, Issue 3, Pages (February 2007)
Antonio Piccoli, Luana Pillon  Kidney International 
Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis  Eero O. Honkanen, Anna-Maija Teppo, Carola.
Presentation transcript:

Volume 54, Issue 4, Pages 1283-1289 (October 1998) Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy  George L. Bakris, Matthew R. Weir, Vincent Dequattro, F. Gilbert McMahon  Kidney International  Volume 54, Issue 4, Pages 1283-1289 (October 1998) DOI: 10.1046/j.1523-1755.1998.00083.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Protocol of blood pressure measured monthly.*GFR and 24-hour urinary excretion of protein, albumin, creatinine, β2-microglobulin and sodium were measured every three months. Abbreviations are: T, trandolapril, V, verapamil SR; T/V, trandolapril + verapamil SR. Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Mean arterial pressure in each group over the one year duration of the study. Abbreviations are: T, trandolapril; V, verapamil SR; T/V, trandolapril + verapamil SR. Symbols are: (□) V; (⋄) T; (▴) T+V. *P < 0.05 compared to either V alone or T alone. Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 The percent reduction from baseline in both proteinuria (▪) and mean arterial pressure () at one year. Abbreviation T/V is trandolapril + verapamil SR.#P < 0.05 difference between albuminuria reduction and MAP in a given group. *P < 0.05 different from other groups of albuminuria reduction. Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 4 Trends in proteinuria over the one year study. Abbreviations are: T, trandolapril; V, verapamil SR; T/V, trandolapril + verapamil SR. Symbols are: (□) V; (⋄) T; (▴) T+V.*P < 0.05 compared to T or V alone. Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 1283-1289DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 1283-1289DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 1283-1289DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 1283-1289DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 1283-1289DOI: (10.1046/j.1523-1755.1998.00083.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.